Ezekiel J Emanuel

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi What cannot be said on television about health care
    Ezekiel J Emanuel
    Department of Clinical Bioethics, The Clinical Center, National Institutes of Health, Bethesda, MD 20892-1156, USA
    JAMA 297:2131-3. 2007
  2. ncbi Managed care, hospice use, site of death, and medical expenditures in the last year of life
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 1156, USA
    Arch Intern Med 162:1722-8. 2002
  3. ncbi Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study
    Christine Pace
    Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Mayland 20892, USA
    AIDS Res Hum Retroviruses 22:837-41. 2006
  4. ncbi Informed consent: practices and views of investigators in a multinational clinical trial
    Lindsay Sabik
    Department of Clinical Bioethics, National Institutes of Health, Bethesda, MD, USA
    IRB 27:13-8. 2005
  5. ncbi Patients' decision-making process regarding participation in phase I oncology research
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1156, USA
    J Clin Oncol 24:4479-84. 2006
  6. ncbi Factors that influence practitioners' interpretations of evidence from alternative medicine trials: a factorial vignette experiment embedded in a national survey
    Jon C Tilburt
    Department of Bioethics, National Institutes of Health, Bethesda, MD 20892, USA
    Med Care 48:341-8. 2010
  7. ncbi Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research
    Lindsay A Hampson
    Department of Bioethics, The Clinical Center, National Institutes of Health, Bethesda, MD 20892 1156, USA
    J Clin Oncol 25:3609-14. 2007
  8. ncbi Patients' views on financial conflicts of interest in cancer research trials
    Lindsay A Hampson
    Department of Clinical Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 355:2330-7. 2006
  9. ncbi Undue inducement: nonsense on stilts?
    Ezekiel J Emanuel
    National Institutes of Health, USA
    Am J Bioeth 5:9-13; discussion W8-11, W17. 2005
  10. ncbi Research with stored biological samples: what do research participants want?
    Donna T Chen
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Arch Intern Med 165:652-5. 2005

Detail Information

Publications77

  1. ncbi What cannot be said on television about health care
    Ezekiel J Emanuel
    Department of Clinical Bioethics, The Clinical Center, National Institutes of Health, Bethesda, MD 20892-1156, USA
    JAMA 297:2131-3. 2007
  2. ncbi Managed care, hospice use, site of death, and medical expenditures in the last year of life
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892 1156, USA
    Arch Intern Med 162:1722-8. 2002
    ..We examined deaths of Medicare beneficiaries in Massachusetts and California to evaluate the effect of managed care on the use of hospice and site of death and to determine how hospice affects the expenditures for the last year of life...
  3. ncbi Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study
    Christine Pace
    Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Mayland 20892, USA
    AIDS Res Hum Retroviruses 22:837-41. 2006
    ..IRB/REC chairs and researchers were less expansive both in who and how they thought a drug should be guaranteed...
  4. ncbi Informed consent: practices and views of investigators in a multinational clinical trial
    Lindsay Sabik
    Department of Clinical Bioethics, National Institutes of Health, Bethesda, MD, USA
    IRB 27:13-8. 2005
  5. ncbi Patients' decision-making process regarding participation in phase I oncology research
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1156, USA
    J Clin Oncol 24:4479-84. 2006
    ..This study assesses the decision-making process of patients enrolling in phase I oncology studies...
  6. ncbi Factors that influence practitioners' interpretations of evidence from alternative medicine trials: a factorial vignette experiment embedded in a national survey
    Jon C Tilburt
    Department of Bioethics, National Institutes of Health, Bethesda, MD 20892, USA
    Med Care 48:341-8. 2010
    ..Clinical trial evidence in controversial areas such as complementary and alternative medicine (CAM) must be approached with an open mind...
  7. ncbi Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research
    Lindsay A Hampson
    Department of Bioethics, The Clinical Center, National Institutes of Health, Bethesda, MD 20892 1156, USA
    J Clin Oncol 25:3609-14. 2007
    ..Using data from American Society of Clinical Oncology (ASCO) Annual Meetings, we determined the frequency, type, and monetary value of researchers' financial interests...
  8. ncbi Patients' views on financial conflicts of interest in cancer research trials
    Lindsay A Hampson
    Department of Clinical Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 355:2330-7. 2006
    ..A substantial minority wanted to be informed about the oversight system to protect against financial conflicts of interest and about researchers' financial interests. Copyright 2006 Massachusetts Medical Society...
  9. ncbi Undue inducement: nonsense on stilts?
    Ezekiel J Emanuel
    National Institutes of Health, USA
    Am J Bioeth 5:9-13; discussion W8-11, W17. 2005
  10. ncbi Research with stored biological samples: what do research participants want?
    Donna T Chen
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, and National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Arch Intern Med 165:652-5. 2005
    ..Many believe consent for each future use is required to respect individuals. Others worry this approach may block important research...
  11. ncbi Why patients continue to participate in clinical research
    David Wendler
    Department of Bioethics, National Institutes of Health, Bldg 10, Room 1C118, Bethesda, MD 20892, USA
    Arch Intern Med 168:1294-9. 2008
    ..While some commentators argue that this process inappropriately exploits patient participants, there are few data available to evaluate this claim...
  12. ncbi Quality-improvement research and informed consent
    Franklin G Miller
    Department of Bioethics, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 358:765-7. 2008
  13. ncbi What is a "minor" increase over minimal risk?
    David Wendler
    Department of Clinical Bioethics, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA
    J Pediatr 147:575-8. 2005
  14. ncbi Principles for allocation of scarce medical interventions
    Govind Persad
    Department of Bioethics, The Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Lancet 373:423-31. 2009
    ..We recommend an alternative system-the complete lives system-which prioritises younger people who have not yet lived a complete life, and also incorporates prognosis, save the most lives, lottery, and instrumental value principles...
  15. ncbi US health aid beyond PEPFAR: the Mother & Child Campaign
    Colleen C Denny
    Department of Bioethics, The Clinical Center, National Institutes of Health, Bethesda, MD 20892-1156, USA
    JAMA 300:2048-51. 2008
  16. ncbi Participants in phase 1 oncology research trials: are they vulnerable?
    Justine Seidenfeld
    Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1156, USA
    Arch Intern Med 168:16-20. 2008
    ....
  17. ncbi Research benefits for hypothetical HIV vaccine trials: The views of Ugandans in the Rakai District
    Christine Grady
    Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    IRB 30:1-7. 2008
  18. ncbi Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit
    David Wendler
    Department of Clinical Bioethics, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    JAMA 294:826-32. 2005
    ..These data also raise the question of whether the federal minimal risk standard may sometimes fail to provide sufficient protection for children, prompting the need to consider alternative standards...
  19. ncbi Circumcision and HIV prevention research: an ethical analysis
    Reidar K Lie
    Department of Clinical Bioethics, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Lancet 368:522-5. 2006
  20. ncbi Undue inducement in clinical research in developing countries: is it a worry?
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Institutes of Health, Building 10 Room 1C118, Bethesda, MD 20892 1156, USA
    Lancet 366:336-40. 2005
  21. ncbi Money and distorted ethical judgments about research: ethical assessment of the TeGenero TGN1412 trial
    Ezekiel J Emanuel
    Department of Clinical Bioethics, The Clinical Center, National Institutes of Health, Bethesda, MD 20892 1156, USA
    Am J Bioeth 7:76-81. 2007
    ....
  22. ncbi Risks and benefits of phase 1 oncology trials, 1991 through 2002
    Elizabeth Horstmann
    Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1156, USA
    N Engl J Med 352:895-904. 2005
    ..Rates of response and toxicity vary, however, among the various types of phase 1 oncology trials...
  23. ncbi The obligation to participate in biomedical research
    G Owen Schaefer
    Department of Bioethics, The Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    JAMA 302:67-72. 2009
    ..Such a shift would be of great aid to the progress of biomedical research, eventually making society significantly healthier and longer lived...
  24. ncbi Chemotherapy use among Medicare beneficiaries at the end of life
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, Building 10, Room 1C118, Bethesda, Maryland 20892-1156, USA
    Ann Intern Med 138:639-43. 2003
    ..The cancer's responsiveness to chemotherapy does not seem to influence whether dying patients receive chemotherapy at the end of life...
  25. ncbi The perfect storm of overutilization
    Ezekiel J Emanuel
    Department of Bioethics, Bldg 10, Room 1C118, National Institutes of Health, Bethesda, MD 20892-1156, USA
    JAMA 299:2789-91. 2008
  26. ncbi The ethics of research on enhancement interventions
    Ori Lev
    Department of Bioethics, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Kennedy Inst Ethics J 20:101-13. 2010
    ..Instead, like any other clinical research, each proposed enhancement study should be reviewed individually to assess whether it fulfills the ethical requirements that make a clinical study permissible...
  27. ncbi Should society allow research ethics boards to be run as for-profit enterprises?
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States
    PLoS Med 3:e309. 2006
    ..Critics argue that for-profit IRBs have a conflict of interest because they generate their income from clients who have a direct financial interest in obtaining approval...
  28. ncbi Medicare's requirement for research participation as a condition of coverage: is it ethical?
    Steven D Pearson
    Department of Clinical Bioethics, National Institutes of Health, Bethesda, MD 20892, USA
    JAMA 296:988-91. 2006
  29. ncbi Why well-insured patients should demand value-based insurance benefits
    Colleen C Denny
    Department of Bioethics, The NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892-1156, USA
    JAMA 297:2515-8. 2007
  30. ncbi Conflict of interest in industry-sponsored drug development
    Ezekiel J Emanuel
    Department of Clinical Bioethics, The Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Adv Hematol Oncol 5:265-7. 2007
  31. ncbi Prescribing "placebo treatments": results of national survey of US internists and rheumatologists
    Jon C Tilburt
    Department of Bioethics, National Institutes of Health, Bethesda, MD 20892, USA
    BMJ 337:a1938. 2008
    ..To describe the attitudes and behaviours regarding placebo treatments, defined as a treatment whose benefits derive from positive patient expectations and not from the physiological mechanism of the treatment itself...
  32. ncbi Case study. Is longer always better? Commentary
    Ezekiel J Emanuel
    Bioethics Department, Clinical Center, National Institutes of Health, USA
    Hastings Cent Rep 38:10-1. 2008
  33. ncbi The quality of informed consent in a clinical research study in Thailand
    Christine Pace
    Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    IRB 27:9-17. 2005
  34. ncbi Who really pays for health care? The myth of "shared responsibility"
    Ezekiel J Emanuel
    Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    JAMA 299:1057-9. 2008
  35. ncbi The problem with single-payer plans
    Ezekiel J Emanuel
    Department of Bioethics, Clinical Center, National Institutes of Health, USA
    Hastings Cent Rep 38:38-41. 2008
  36. ncbi Descriptions of benefits and risks in consent forms for phase 1 oncology trials
    Sam Horng
    Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1156, USA
    N Engl J Med 347:2134-40. 2002
    ..Although there is room for improvement, the substance of these forms is unlikely to be the primary source of misunderstanding by subjects in phase 1 oncology trials...
  37. ncbi Changing premed requirements and the medical curriculum
    Ezekiel J Emanuel
    Department of Clinical Bioethics, The Clinical Center, National Institutes of Health, Bethesda, MD 20892-1156, USA
    JAMA 296:1128-31. 2006
  38. ncbi Essential elements of a technology and outcomes assessment initiative
    Ezekiel J Emanuel
    Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    JAMA 298:1323-5. 2007
  39. ncbi Evaluating the risks of clinical research
    Annette Rid
    Department of Bioethics, NIH Clinical Center, Bethesda, MD 20892, USA
    JAMA 304:1472-9. 2010
    ....
  40. ncbi The standard of care debate: can research in developing countries be both ethical and responsive to those countries' health needs?
    David Wendler
    Department of Clinical Bioethics, National Institutes of Health, Building 10, Room 1C118, Bethesda, MD 20892
    Am J Public Health 94:923-8. 2004
    ....
  41. ncbi "Physician-assisted suicide among Oregon cancer patients": a fading issue
    Colleen C Denny
    Department of Clinical Bioethics at the National Institutes of Health, Bethesda, USA
    J Clin Ethics 17:39-42; discussion 43-5. 2006
  42. ncbi The cost-coverage trade-off: "it's health care costs, stupid"
    Ezekiel J Emanuel
    Department of Bioethics, The Clinical Center, National Institutes of Health, Bethesda, Maryland 20892-1156, USA
    JAMA 299:947-9. 2008
  43. ncbi Technology licensing: lessons from the US experience
    Gregory K Sobolski
    Department of Clinical Bioethics, National Institutes of Health, Bethesda, MD 20892, USA
    JAMA 294:3137-40. 2005
  44. ncbi Ethics. The ethics of international research with abandoned children
    Joseph Millum
    Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD 20892-1156, USA
    Science 318:1874-5. 2007
  45. ncbi Ethical issues concerning research in complementary and alternative medicine
    Franklin G Miller
    Department of Clinical Bioethics, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    JAMA 291:599-604. 2004
    ..In addition, we explore the legitimacy of providing CAM and conventional therapies that have been demonstrated to be effective only by virtue of the placebo effect...
  46. ncbi The costs of conducting clinical research
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 21:4145-50. 2003
    ..CONCLUSION: Based on the results of our mock trial, the time required for nontreatment trial activities is considerable, and the associated costs are substantial...
  47. ncbi Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and Mali
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20892, USA
    Am J Trop Med Hyg 83:868-72. 2010
    ....
  48. ncbi Four paradigms of clinical research and research oversight
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Camb Q Healthc Ethics 16:82-96. 2007
  49. ncbi Access and ability to pay: the ethics of a tiered health care system
    Benjamin J Krohmal
    Department of Clinical Bioethics at the Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Arch Intern Med 167:433-7. 2007
  50. ncbi Talking with terminally ill patients and their caregivers about death, dying, and bereavement: is it stressful? Is it helpful?
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Arch Intern Med 164:1999-2004. 2004
    ..This study was conducted to assess whether interviewing terminally ill patients and their caregivers about death, dying, and bereavement is stressful and/or helpful...
  51. ncbi Public health. Who should get influenza vaccine when not all can?
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1156, USA
    Science 312:854-5. 2006
  52. ncbi Does the evidence make a difference in consumer behavior? Sales of supplements before and after publication of negative research results
    Jon C Tilburt
    Department of Bioethics, National Institutes of Health, Bethesda, MD, USA
    J Gen Intern Med 23:1495-8. 2008
    ..To determine if the public consumption of herbs, vitamins, and supplements changes in light of emerging negative evidence...
  53. ncbi Euthanasia and physician-assisted suicide: a review of the empirical data from the United States
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, Bldg 10, Room 1C118, National Institutes of Health, Bethesda, MD 20892-1156, USA
    Arch Intern Med 162:142-52. 2002
  54. ncbi The prognosis for changes in end-of-life care after the Schiavo case
    Lindsay A Hampson
    Warren G. Magnuson Clinical Center, National Institutes of Health, in Bethesda, Maryland, USA
    Health Aff (Millwood) 24:972-5. 2005
    ..But despite court cases and national consensus that these are private and not legislative matters, the Schiavo case is unlikely to change practices except to increase the number of Americans who complete living wills...
  55. ncbi The patents-based pharmaceutical development process: rationale, problems, and potential reforms
    John H Barton
    Department of Clinical Bioethics, National Institutes of Health, Bethesda, MD 20892-1156, USA
    JAMA 294:2075-82. 2005
    ....
  56. ncbi Ethics of phase 1 oncology studies: reexamining the arguments and data
    Manish Agrawal
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1156, USA
    JAMA 290:1075-82. 2003
    ..Overall, it appears that phase 1 oncology trials satisfy the requirement for a favorable risk-benefit ratio and that patients who enroll provide adequate informed consent...
  57. ncbi Oversight of human participants research: identifying problems to evaluate reform proposals
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1156, USA
    Ann Intern Med 141:282-91. 2004
    ....
  58. ncbi What makes clinical research in developing countries ethical? The benchmarks of ethical research
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1156, USA
    J Infect Dis 189:930-7. 2004
  59. ncbi The current state of medical school education in bioethics, health law, and health economics
    Govind C Persad
    Department of Bioethics, National Institutes of Health, USA
    J Law Med Ethics 36:89-94, 4. 2008
    ..This suggests that medical schools should reevaluate their curricula and instructors in bioethics, health law, and health economics...
  60. ncbi The lessons of SARS
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1156, USA
    Ann Intern Med 139:589-91. 2003
    ..These lessons will be valuable far beyond the SARS episode...
  61. ncbi The ethics of paying for children's participation in research
    David Wendler
    Department of Clinical Bioethics, National Institutes of Health, Bethesda, Maryland, 20892, USA
    J Pediatr 141:166-71. 2002
  62. ncbi The general agreement on trade in services: implications for health policymakers
    Leah Belsky
    Department of Clinical Bioethics, National Institutes of Health, Bethesda, Maryland, USA
    Health Aff (Millwood) 23:137-45. 2004
    ..We explain the rationale behind the agreement and discuss its scope. We also address the major controversies surrounding the GATS and their implications for the U.S. health care system...
  63. ncbi Evaluating community-based health initiatives: identifying the characteristics of successful initiatives and evaluations
    Ezekiel J Emanuel
    Department of Clinical Bioethics, Warren G. Magnuson Clinical Center, National Institutes of Health, USA
    J Health Polit Policy Law 27:105-8. 2002
  64. ncbi Ending concerns about undue inducement
    Ezekiel J Emanuel
    J Law Med Ethics 32:100-5. 2004
  65. ncbi Managing end-of-life care: comparing the experiences of terminally Ill patients in managed care and fee for service
    Julia Slutsman
    Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
    J Am Geriatr Soc 50:2077-83. 2002
    ..Finally, terminally ill patients in MCOs did not show better experiences than those in FFS on any outcome measure. Additional research is required to explore how MCOs may improve upon the care available to dying patients...
  66. ncbi Regional ethics organizations for protection of human research participants
    Anne Wood
    School of Law, University of California, Berkeley, Berkeley, California 94720-7200, USA
    Nat Med 10:1283-8. 2004
  67. ncbi The ethics of research in developing countries: assessing voluntariness
    Christine A Pace
    Harvard Medical School, Boston, Massachusetts, USA
    Lancet 365:11-2. 2005
  68. ncbi Does random treatment assignment cause harm to research participants?
    Cary P Gross
    Section of General Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    PLoS Med 3:e188. 2006
    ..We therefore performed a systematic review to quantify the differences in health outcomes between randomized trial participants and eligible non-participants...
  69. ncbi Who's caring for whom? Differing perspectives between seriously ill patients and their family caregivers
    Joshua M Hauser
    Buehler Center on Aging, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Am J Hosp Palliat Care 23:105-12. 2006
    ..Consistent sociodemographic or clinical predictors of nonconcordant responses were not found. These data suggest important ways that patient and caregiver reports of the same experience vary...
  70. ncbi Clarifying confusions about coercion
    Jennifer S Hawkins
    University of Toronto
    Hastings Cent Rep 35:16-9. 2005
  71. ncbi Depression, euthanasia, and improving end-of-life care
    Ezekiel J Emanuel
    J Clin Oncol 23:6456-8. 2005
  72. ncbi What are bioethicists doing about health care reform?
    Ezekiel J Emanuel
    Hastings Cent Rep 38:12-3. 2008
  73. ncbi Health care vouchers--a proposal for universal coverage
    Ezekiel J Emanuel
    Posterity Project, Chicago, USA
    N Engl J Med 352:1255-60. 2005
  74. ncbi Legal reforms necessary to promote delivery system innovation
    Timothy Stoltzfus Jost
    Washington and Lee School of Law, Lexington, Virginia, USA
    JAMA 299:2561-3. 2008
  75. ncbi Risks and benefits associated with novel phase 1 oncology trial designs
    Shlomo A Koyfman
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA
    Cancer 110:1115-24. 2007
    ..The prevalence of several novel trial designs and their association with a variety of clinical endpoints was evaluated...
  76. ncbi Community permission for medical research in developing countries
    Dapa A Diallo
    Department of Hematology, Malaria Research and Training Center, Faculty of Medicine, Pharmacy and Dentistry, University of Bamako, Mali
    Clin Infect Dis 41:255-9. 2005
    ..Far from competing with the individual informed consent process, the process of obtaining community permission both initiated and facilitated the process of disclosure for individual informed consent...
  77. ncbi End-of-life care: the authors respond
    Lindsay A Hampson
    University of Michigan School of Medicine, Ann Arbor, MichiganNational Institutes of Health, Bethesda, Maryland
    Health Aff (Millwood) 24:1687-8. 2005